Bayer Receives FDA Fast-Track Designation for Next-Generation Anticoagulant.

The article reports on the Fast-Track designation received by Bayer from the U.S. Food and Drug Administration (FDA) for its investigational anticoagulant asundexian (BAY243334). Topics discussed include information on asundexian, how to receive Fast Track designation, and clinical trials that are evaluating proper dosing and safety of asundexian.